Ashish Udhrain, MD
Hematology & Oncology · Metairie, LANPI 1013980853
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by AstraZeneca at 39.1% of the total. Reporting peaked in 2019 at $35,594 and has fallen 87.3% since, to $4,524 in 2025. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $410.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Pfizer$9K
- Sanofi$6K
- Taiho Oncology, Inc.$2K
- Karyopharm Therapeutics Inc.$2K
- plus $5K from 35 others
What the payments were for
- Consulting fees$44,63559%
- Speaking & faculty fees$21,85029%
- Travel & lodging$4,6596%
- Food & beverage$4,2456%
- Education$1390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $29,519 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $22,619 |
| Pfizer | 10 | $8,797 |
| Sanofi | 12 | $6,428 |
| Taiho Oncology, Inc. | 2 | $1,667 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Astrazeneca UK Limited | 1 | $1,388 |
| Daiichi Sankyo Inc. | 4 | $1,185 |
| Novartis | 15 | $313 |
| Beigene USA, Inc. | 6 | $208 |
| Merck | 9 | $179 |
| Lilly USA, LLC | 4 | $149 |
| Bristol Myers Squibb | 8 | $142 |
| Bayer | 7 | $130 |
| Exelixis Inc. | 5 | $118 |
| AVEO Pharmaceuticals, Inc. | 2 | $111 |
| Boehringer Ingelheim | 1 | $94 |
| Johnson & Johnson | 5 | $88 |
| Astellas Pharma US Inc | 3 | $82 |
| Jazz Pharmaceuticals Inc. | 3 | $80 |
| Eisai Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Sobi, Inc | 2 | $54 |
| AbbVie | 2 | $53 |
| Springworks Therapeutics, Inc. | 3 | $51 |
| Incyte Corporation | 2 | $41 |
| Genentech USA, Inc. | 2 | $40 |
| Seagen Inc. | 3 | $37 |
| Gilead | 2 | $34 |
| Immunocore Limited | 1 | $34 |
| GSK | 2 | $31 |
| Stemline Therapeutics Inc. | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Amgen | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Inari Medical, Inc. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $18 |
| CTI Biopharma Corp. | 1 | $17 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,528 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 38 | $616,747 |
| ImbruvicaIbrutinib | 27 | $497,763 |
| IbrancePalbociclib | 26 | $435,384 |
| JaypircaPirtobrutinib | 14 | $350,944 |
| Abiraterone Acetate | 71 | $287,700 |
| TafinlarDabrafenib Mesylate | 18 | $225,491 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $206,368 |
| RevlimidLenalidomide | 12 | $205,922 |
| AlecensaAlectinib Hcl | 12 | $167,683 |
| InlytaAxitinib | 11 | $148,377 |
| BrukinsaZanubrutinib | 12 | $141,922 |
| EliquisApixaban | 18 | $17,091 |
| Imatinib Mesylate | 15 | $15,011 |
| Anastrozole | 227 | $4,444 |
| Ondansetron OdtOndansetron | 83 | $2,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tafinlar, Mekinist | $313 | $1,048,60768 claims |
| PfizerIbrance, Inlyta, Eliquis | $8,797 | $600,85155 claims |
| Lilly USA, LLCJaypirca | $149 | $350,94414 claims |
| Bristol Myers SquibbRevlimid | $142 | $205,92212 claims |
| Genentech USA, Inc.Alecensa | $40 | $167,68312 claims |
| Beigene USA, Inc.Brukinsa | $208 | $141,92212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Metairie
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
- Sanjay JunejaBaton Rouge$346K
- Lingling duNew Orleans$173K
- Kamran ShahidLake Charles$155K
- Kevin GallagherShreveport$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.